Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 4/20 | 0.53 |
| ▸ | CTSS | P25774 | 3/20 | 0.53 |
| ▸ | CTSL | P07711 | 2/20 | 0.53 |
| ▸ | CTSB | P07858 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18086889 | 0.88 | CTSK (0.55) | SYKLMNASMN1; SMN2CTSKCTSS | |
| SCHEMBL5370600 | 0.88 | LMNA (0.55) | SYKLMNASMN1; SMN2CTSKCTSS | |
| SCHEMBL28522803 | 0.87 | LMNA (0.54) | SYKLMNASMN1; SMN2CTSKCTSS | |
| SCHEMBL20681083 | 0.87 | LMNA (0.54) | SYKLMNASMN1; SMN2CTSKCTSS | |
| SCHEMBL1287197 | 0.87 | HTT (0.55) | SYKLMNASMN1; SMN2CTSKCTSS | |
| SCHEMBL28522801 | 0.87 | LMNA (0.54) | SYKLMNASMN1; SMN2CTSKCTSS | |
| SCHEMBL15932531 | 0.86 | SLC1A3 (0.53) | SYKLMNASMN1; SMN2CTSKCTSS | |
| SCHEMBL18085401 | 0.86 | CTSL (0.57) | SYKLMNASMN1; SMN2CTSKCTSS | |
| SCHEMBL9293928 | 0.86 | LMNA (0.59) | SYKLMNASMN1; SMN2CTSKCTSS | |
| SCHEMBL29375182 | 0.85 | LMNA (0.60) | LMNASMN1; SMN2CTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110016020-A | Compound or pharmaceutically acceptable salt thereof, application and pharmaceutical composition thereof | 铁木医药有限公司 | 2019-07-16 | — | — | CN | disclosed |
| CN-109384778-A | Use of a compound or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a disease, health condition or disorder | 铁木医药有限公司 | 2019-02-26 | — | — | CN | disclosed |
| CN-109369635-A | Compound or pharmaceutically acceptable salt thereof, application and pharmaceutical composition thereof | 铁木医药有限公司 | 2019-02-22 | — | — | CN | disclosed |
| CN-108912111-A | compounds and pharmaceutical compositions | 铁木医药有限公司 | 2018-11-30 | — | — | CN | disclosed |
| CN-105408328-B | sGC stimulators | 铁木医药有限公司 | 2018-11-16 | — | — | CN | disclosed |
| US-20180133244-A1 | METHODS AND COMPOSITIONS FOR SELECTIVELY REMOVING POTASSIUM ION FROM THE GASTROINTESTINAL TRACT OF A MAMMAL | VIFOR (INTERNATIONAL) LTD. (CH) | 2018-05-17 | — | — | US | disclosed |
| EP-0793674-A1 | HUMAN NEUTROPHIL ELASTASE INHIBITORS | CORTECH, INC. (US) | 1997-09-10 | — | — | EP | disclosed |
| WO-1996016080-A1 | HUMAN NEUTROPHIL ELASTASE INHIBITORS | CORTECH, INC. (US) | 1996-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133244-A1 | METHODS AND COMPOSITIONS FOR SELECTIVELY REMOVING POTASSIUM ION FROM THE GASTROINTESTINAL TRACT OF A MAMMAL | KCNN3, KCNH3, KCNH2 | SYK 3286/4885LMNA 563/4885SMN1; SMN2 3911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.